Ovarian Cancer Symptoms and Treatment

Ovarian Cancer Cells Are Killed By Platinum-Phosphate Compounds

hareyan — Wed, 19 Nov 2008 10:16:00 -0600

A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences.

Protein compels ovarian cancer cells to eat themselves

hareyan — Sat, 15 Nov 2008 23:34:45 -0600

A protein known to inhibit the growth of ovarian cancer works in part by forcing cancer cells to eat themselves until they die, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 15 issue of Cancer Research.

The research team also found that expression of the protein, known as PEA-15, is an independent indicator of a woman's prospects for surviving ovarian cancer, said senior author Naoto T. Ueno, M.D., Ph.D. associate professor of breast medical oncology.

Novel Blood Test Detects Ovarian Cancer

ruzik_tuzik — Wed, 12 Nov 2008 00:38:56 -0600

A pilot study by researchers at The Ohio State University Comprehensive Cancer Center found that a novel blood test that screens for microRNAs can reliably detect ovarian cancer, even among patients who test negative for the deadly disease with the widely used CA-125 blood test.

“The early detection of ovarian cancer is the Holy Grail,” says lead investigator Dr. David E. Cohn, a gynecologic oncologist and researcher at The Ohio State University Comprehensive Cancer – James Cancer Hospital and Solove Research Institute.

Ovarian Cancer Patients Benefit From Telcyta-Pegylated Liposomal Doxorubicin Trial

ruzik_tuzik — Thu, 30 Oct 2008 02:31:23 -0500

Telik, Inc. (Nasdaq: TELK) today announced top-line results from an interrupted Phase 3 randomized study of Telcyta (canfosfamide HCL) in combination with pegylated liposomal doxorubicin (PLD) versus PLD alone in second-line therapy in platinum refractory, primary platinum resistant or secondary platinum resistant ovarian cancer.

FDA Says New Ovarian Cancer Test is Illegal to Sell

Toni Brayer MD — Thu, 09 Oct 2008 03:14:47 -0500

The FDA has halted sales of a blood test called Ova Sure that measures six proteins it says can diagnose ovarian cancer in women. Laboratory Corp of America side stepped the usual FDA review process and was notified that there is not enough research data to market the test. The FDA says Ova Sure, developed by researchers at Yale School of Medicine, is illegal to sell at this time.

Michigan Observes National Ovarian Cancer Awareness Month

ruzik_tuzik — Wed, 10 Sep 2008 11:20:14 -0500

As Michigan observes September as National Ovarian Cancer Awareness Month, it is an opportunity to raise awareness of the risk factors and signs and symptoms of this deadly disease.

Ovarian cancer accounts for about 3% of all cancers among women and ranks 2nd among gynecological cancers. It causes more deaths than any other cancer of the female reproductive system.

Early Detection Essential In Fight Against Ovarian Cancer

ruzik_tuzik — Tue, 09 Sep 2008 08:22:35 -0500

Ovarian cancer is often referred to as the silent killer due to the advanced stage at which most cases are discovered. In the last 30 years, however, medical advancements have allowed us to wage a better fight against the disease, thereby increasing survival rates. As we enter into Ovarian Cancer Awareness Month, experts at Northwestern Memorial stress the importance of knowing your risk and being able to recognize potential warning signs.

Symptoms, Blood Test Accurately Detect Ovarian Cancer

hareyan — Tue, 24 Jun 2008 09:45:16 -0500

The combination of blood test and a number of symptoms increase ovarian cancer detection accuracy by 20 percent.

Helping Fight Ovarian Cancer

hareyan — Thu, 29 May 2008 09:06:10 -0500

Electrolux and Kelly Ripa have teamed up for a charity auction featuring a stylish collection of designer handbags from Ripa's personal collection. All proceeds will go to help fight ovarian cancer.

BSI-201 Demonstrates Significant Tumor Growth Inhibition In Ovarian Cancer Studies

hareyan — Tue, 15 Apr 2008 08:27:34 -0500

BiPar Sciences announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models.